Risk of adverse outcomes associated with cardiac sarcoidosis diagnostic schemes

Rahul Myadam, Virginia Commonwealth University, Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Richmond, Virginia, USA.
Thomas C. Crawford, Department of Cardiology, University of Michigan Health System, Ann Arbor, Michigan, USA.Follow
Frank M. Bogun, Department of Cardiology, University of Michigan Health System, Ann Arbor, Michigan, USA.Follow
Xiaokui Gu, Department of Cardiology, University of Michigan Health System, Ann Arbor, Michigan, USA.
Kenneth A. Ellenbogen, Virginia Commonwealth University, Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Richmond, Virginia, USA.
Shilpa Jasti, Virginia Commonwealth University, Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Richmond, Virginia, USA.
Alexandru B. Chicos, Division of Cardiology, Department of Medicine, and the Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Northwestern University, Chicago, Illinois, USA.Follow
Henri Roukoz, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Peter J. Zimetbaum, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Steven J. Kalbfleisch, Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Francis D. Murgatroyd, Department of Cardiology King's College Hospital NHS Foundation Trust London, London, UK.
David A. Steckman, Division of Cardiology, Albany Medical Center, Albany, New York, USA.
Lynda E. Rosenfeld, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Ann C. Garlitski, The New England Cardiac Arrhythmia Center, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
Kyoko Soejima, Kyorin University School of Medicine, Tokyo, Japan.
Adarsh K. Bhan, Advocate Aurora HealthFollow
et al

Affiliations

Advocate Christ Medical Center

Abstract

Background:Multiple cardiac sarcoidosis (CS) diagnostic schemes have been published.

Objectives:This study aims to evaluate the association of different CS diagnostic schemes with adverse outcomes. The diagnostic schemes evaluated were 1993, 2006, and 2017 Japanese criteria and the 2014 Heart Rhythm Society criteria.

Methods:Data were collected from the Cardiac Sarcoidosis Consortium, an international registry of CS patients. Outcome events were any of the following: all-cause mortality, left ventricular assist device placement, heart transplantation, and appropriate implantable cardioverter-defibrillator therapy. Logistic regression analysis evaluated the association of outcomes with each CS diagnostic scheme.

Results:A total of 587 subjects met the following criteria: 1993 Japanese (n = 310, 52.8%), 2006 Japanese (n = 312, 53.2%), 2014 Heart Rhythm Society (n = 480, 81.8%), and 2017 Japanese (n = 112, 19.1%). Patients who met the 1993 criteria were more likely to experience an event than patients who did not (n = 109 of 310, 35.2% vs n = 59 of 277, 21.3%; OR: 2.00; 95% CI: 1.38-2.90; P < 0.001). Similarly, patients who met the 2006 criteria were more likely to have an event than patients who did not (n = 116 of 312, 37.2% vs n = 52 of 275, 18.9%; OR: 2.54; 95% CI: 1.74-3.71; P < 0.001). There was no statistically significant association between the occurrence of an event and whether a patient met the 2014 or the 2017 criteria (OR: 1.39; 95% CI: 0.85-2.27; P = 0.18 or OR: 1.51; 95% CI: 0.97-2.33; P = 0.067, respectively).

Conclusions:CS patients who met the 1993 and the 2006 criteria had higher odds of adverse clinical outcomes. Future research is needed to prospectively evaluate existing diagnostic schemes and develop new risk models for this complex disease.

Type

Article

PubMed ID

37227359

Teammate Access


 

Share

COinS